The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Achieved record consumable revenue and units, driven by a growing installed base and higher system utilization across the top 20 pharma customers.

Attributed the 15% record gross margin to successful execution of margin expansion strategies, including manufacturing efficiencies and service productivity improvements.

Observed a strategic shift in customer behavior toward integrating the Growth Direct platform into broader automation, digital, and data enablement workflows.

Reported that the MilliporeSigma partnership is expanding the commercial funnel into new geographies and adjacent markets, though it remains in the early stages.

Noted that peer-to-peer validation through regional 'Growth Direct Day' events remains a primary driver for accelerating adoption and purchasing decisions.

Highlighted that the business fundamentals are stronger than ever due to a larger installed base and improved visibility into future recurring revenue growth.

Increased full-year validation guidance to at least 27 systems based on a strong pipeline and momentum entering the second half of 2026.

Anticipates fourth-quarter gross margins in the mid-to-high 20% range, supported by material cost reductions and operating leverage from higher volumes.

Expects MilliporeSigma's contribution to system placements to increase meaningfully in the second half of 2026 and continue into 2027.

Projects U.S. reshoring and biomanufacturing capacity expansion to become increasingly meaningful growth contributors starting in mid-to-late 2027.

Maintains a long-term target of 50% gross margin and positive cash flow by the end of 2028, supported by average annual revenue growth greater than 20%.

Executed a focused efficiency program to streamline functions, expected to reduce annual expenses by approximately $3 million starting in 2027.

Identified temporary working capital headwinds in the first half of 2026 due to inventory replenishment and atypical cash collection timing from Q4 2025 placements.

Reported a $10.3 million adjusted EBITDA loss for Q2, with higher gross margins offset by non-recurring corporate expenses.

Confirmed access to a $10 million debt tranche from Trinity Capital remains contingent on achieving specific milestones later this year.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management clarified that while MilliporeSigma will not fulfill their full annual commitment in the calendar year, a significant acceleration is expected in the second half.

The partnership is opening access to previously unreachable sites within existing customer networks and new geographies like South America.

Q3 consumable revenue is expected to be relatively flat compared to the record Q2, with a sequential step-up anticipated in Q4.

Current pull-through growth is trending in the high-single digits per validated system, reflecting both new customer onboarding and increased routine use.

Margin improvement is driven by material cost reductions in systems and the implementation of real-time performance metrics to improve consumable line throughput.

Management expects 2027 gross margins to be higher than the 2026 exit rate, despite typical quarterly seasonality.

Procurement initiatives leveraged through MilliporeSigma are currently in the validation phase and are expected to impact margins starting in 2027 rather than 2026.

The CAR-T market remains a high-growth area where the platform's speed and automation provide a critical ROI for manufacturers.

Strong consumable performance in the quarter was partially attributed to robust manufacturing activity within the cell and gene therapy sector.